- Home
- MFIN vs AMRN Comparison
MFIN vs AMRN Comparison
Compare MFIN & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFIN
- AMRN
- Stock Information
- Founded
- MFIN 1995
- AMRN 1989
- Country
- MFIN United States
- AMRN Ireland
- Employees
- MFIN N/A
- AMRN N/A
- Industry
- MFIN Finance: Consumer Services
- AMRN Biotechnology: Pharmaceutical Preparations
- Sector
- MFIN Finance
- AMRN Health Care
- Exchange
- MFIN Nasdaq
- AMRN Nasdaq
- Market Cap
- MFIN 224.2M
- AMRN 216.0M
- IPO Year
- MFIN 1996
- AMRN 1993
- Fundamental
- Price
- MFIN $9.70
- AMRN $16.51
- Analyst Decision
- MFIN
- AMRN Strong Sell
- Analyst Count
- MFIN 0
- AMRN 1
- Target Price
- MFIN N/A
- AMRN $12.00
- AVG Volume (30 Days)
- MFIN 60.8K
- AMRN 180.2K
- Earning Date
- MFIN 07-29-2025
- AMRN 07-30-2025
- Dividend Yield
- MFIN 5.02%
- AMRN N/A
- EPS Growth
- MFIN N/A
- AMRN N/A
- EPS
- MFIN 1.60
- AMRN N/A
- Revenue
- MFIN $316,751,000.00
- AMRN $214,112,000.00
- Revenue This Year
- MFIN N/A
- AMRN N/A
- Revenue Next Year
- MFIN $5.24
- AMRN $7.88
- P/E Ratio
- MFIN $5.98
- AMRN N/A
- Revenue Growth
- MFIN 13.91
- AMRN N/A
- 52 Week Low
- MFIN $7.21
- AMRN $7.08
- 52 Week High
- MFIN $10.50
- AMRN $17.18
- Technical
- Relative Strength Index (RSI)
- MFIN 58.94
- AMRN 71.62
- Support Level
- MFIN $8.73
- AMRN $12.30
- Resistance Level
- MFIN $9.49
- AMRN $17.18
- Average True Range (ATR)
- MFIN 0.35
- AMRN 1.09
- MACD
- MFIN 0.01
- AMRN 0.26
- Stochastic Oscillator
- MFIN 100.00
- AMRN 73.61
About MFIN Medallion Financial Corp.
Medallion Financial Corp is a finance company that originates and services loans in various industries. The five operating segments are, (1) recreation, (2) home improvement, (3) commercial, (4) taxi medallion, and (5) strategic partnership loans. The company generates maximum revenue from the Recreation segment.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.